Allos reports lymphoma data

Allos (NASDAQ:ALTH) said interim data from the pivotal Phase II PROPEL trial of pralatrexate ( PDX) to treat relapsed or refractory peripheral T cell lymphoma (PTCL) showed that 19 of 65 evaluable pat...